UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 21, 2019

 

Heyu Biological Technology Corporation

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   000-26731   87-0627910
(State or Other Jurisdiction of
Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification Number)

 

4th Floor, No. 10 Building, Xinglin Bay Business Operation Center,

Jimei District, Xiamen City,

Fujian Province, China 361022

(Address of Principal Executive Offices, Zip Code)

Registrant’s telephone number, including area code: (86) 158 5924 0902

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On March 15, 2019, Heyu Biological Technology Corporation, a Nevada corporation (the “Company”), with the approval of its Board of Directors, entered into a Share Cancellation Agreement (the “Share Cancellation Agreement”) with Mr. Ban Siong Ang, the President, Chief Executive Officer, and Chairman of the Board of Directors of the Company (“Mr. Ang”). Pursuant to the Share Cancellation Agreement, the Company and Mr. Ang agreed to cancel 109,006,861 shares of common stock of the Company previously issued to Mr. Ang.

 

The foregoing description of the terms of the Share Cancellation Agreement and the transaction contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Share Cancellation Agreement, which is attached hereto as Exhibit 10.1.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit    
Number   Exhibit Title  
10.1   Share Cancellation Agreement with Ban Siong Ang dated March 15, 2019

 

1  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Heyu Biological Technology Corporation
     
  By: /s/ Ban Siong Ang
  Name: Ban Siong Ang
  Title: Chief Executive Officer
     
  Dated: March 21, 2019

 

 

2  

Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Heyu Biological Technology (PK) Charts.
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Heyu Biological Technology (PK) Charts.